Blue Light Cystoscopy Reveals Hidden Bladder Tumors, Improves Cancer Staging in Major Registry Study
Key Insights
New data from a 2,854-patient registry study shows Blue Light Cystoscopy detected additional malignant lesions in 7% of cases that were missed by standard white light examination.
The enhanced detection capabilities led to cancer upstaging in 9.3% of cases, potentially altering treatment decisions regarding intravesical therapy and surgical interventions.
The study revealed 335 additional tumors detected only by Blue Light Cystoscopy, with 43% being carcinoma in-situ (search) and 40% representing high-grade tumors.
Results from a large-scale U.S. bladder cancer (search) registry study presented at the 2025 ASCO Genitourinary Cancers Symposium demonstrate the crucial role of Blue Light Cystoscopy (BLC) in improving cancer detection and staging accuracy. The research, conducted at multiple centers, analyzed data from 2,854 patients with non-muscle-invasive bladder cancer (search) (NMIBC).
Enhanced Detection of Hidden Tumors
The study revealed that BLC with Cysview identified malignant lesions in 201 patients (7%) that were completely missed by conventional white light cystoscopy (WLC). These findings represent a significant advancement in diagnostic capabilities, as traditional methods would have left these cancers undetected.
Among the 335 additional tumors detected exclusively through BLC:
- 145 (43%) were carcinoma in-situ (CIS)
- 95 (28%) were high-grade Ta tumors
- 53 (16%) were low-grade Ta tumors
- 37 (11%) were high-grade T1 tumors
- 5 (1%) were high-grade T2 tumors
Clinical Impact on Patient Management
The enhanced detection capabilities of BLC led to upgrading or upstaging in 9.3% of cases, significantly impacting treatment decisions. Dr. Alireza Ghoreifi from Duke University Medical Center, who presented the findings, emphasized that these staging changes directly influence critical treatment decisions, including:
- The appropriate implementation of intravesical therapy
- Duration of treatment protocols
- Timing considerations for radical cystectomy
Disease Burden Context
The findings are particularly significant given the global burden of bladder cancer (search), which ranks as the 8th most common cancer worldwide and the 5th most common in men. With 614,000 new cases diagnosed in 2022 and a high recurrence rate of up to 78% over five years, improved detection methods are crucial for patient outcomes.
Study Framework and Future Implications
The data comes from Photocure (search)'s U.S. Blue Light Cystoscopy with Cysview Registry, established in 2014. This ongoing registry, which aims to enroll 4,400 patients, provides valuable real-world evidence of BLC's clinical utility. The results are expected to inform future studies on how BLC can enhance precision diagnostics and optimize NMIBC patient management strategies.